ADAMTSL4 and glioblastoma: Despite not altering the proportion of specific immune cell types, high ADAMTSL4 expression was linked to lower tumor purity, a more complex immune microenvironment, and significantly poorer overall survival, indicating its potential as a prognostic and circulating biomarker for immune response in GBM (68–70).